10x Genomics, Inc. — Director's Dealing 2022

Sep 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2022-09-12

Reporting Person: Saxonov Serge (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-12	Class A Common Stock	M	11500	$1.2	Acquired	977602	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-12	Stock Option (right to buy)	$1.2	M	11500	Disposed	2027-10-18	Class A Common Stock (11500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	2487	Indirect
Class A Common Stock	89960	Indirect

Footnotes

F1: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

F2: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F3: This option, originally for 300,000 shares, of which 258,965 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.